Clinical predictive factors of pathologic complete response in locally advanced rectal cancer

Predictive factors of pathologic complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC) are still not identified. The purpose of this study was to define them. Data from consecutive LARC patients treated between January 2008 and June 2014 at our I...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2016-05, Vol.7 (22), p.33374-33380
Main Authors: De Felice, Francesca, Izzo, Luciano, Musio, Daniela, Magnante, Anna Lisa, Bulzonetti, Nadia, Pugliese, Federico, Izzo, Paolo, Di Cello, Pierfrancesco, Lucchetti, Pietro, Izzo, Sara, Tombolini, Vincenzo
Format: Article
Language:English
Subjects:
Aged
Chemoradiotherapy, Adjuvant
Chi-Square Distribution
Clinical Research Paper
Female
Humans
Logistic Models
Male
Multivariate Analysis
Neoadjuvant Therapy
Neoplasm Staging
Odds Ratio
Rectal Neoplasms - pathology
Rectal Neoplasms - therapy
Retrospective Studies
Risk Factors
Rome
Time Factors
Treatment Outcome
Tumor Burden
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Predictive factors of pathologic complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC) are still not identified. The purpose of this study was to define them. Data from consecutive LARC patients treated between January 2008 and June 2014 at our Institution were included in the analysis. All patients were treated with a long course of nCRT. Demographics, initial diagnosis and tumor extension details, as well as treatment modalities characteristics were included in the univariate and logistic regression analysis. In total 99 patients received nCRT, of whom 23 patients (23.2%) achieved pCR. Patients with and without pCR were similar in term of age, sex, comobidities, BMI and tumor characteristics. Multivariate logistic regression indicated that pre-treatment tumor size ≤ 5 cm was a significant predictor for pCR (p = 0.035), whereas clinical N stage only showed a positive trend (p = 0.084). Tumor size at diagnosis could be used to predict pCR, and thus to individualize therapy in LARC patients management. Validation in other studies is needed.
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.8133